Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2726
CALL
SolarEdge
SEDG
$1.98B
| $2.57M | ﹤0.01% |
+89,100
| New | +$3.11M |
|
|
CFLT
2727
DELISTED
Confluent
CFLT
| $2.56M | ﹤0.01% |
84,669
-259,500
| -75% | -$6.37M |
|
|
IAUX
2728
i-80 Gold Corp
IAUX
$1.52B
| $2.56M | ﹤0.01% |
1,753,328
+1,605,544
| +1,086% | +$1.83M |
|
2729
Albany International
AIN
$1.81B
| $2.55M | ﹤0.01% |
50,289
+7,346
| +17% | +$380K |
|
2730
Clearfield
CLFD
$395M
| $2.55M | ﹤0.01% |
87,344
+1,682
| +2% | +$54.1K |
|
|
AL
2731
DELISTED
Air Lease Corp
AL
| $2.54M | ﹤0.01% |
39,616
-17,989
| -31% | -$1.15M |
|
2732
Capitol Federal Financial
CFFN
$1.1B
| $2.54M | ﹤0.01% |
373,485
+44,564
| +14% | +$290K |
|
2733
MiMedx Group
MDXG
$624M
| $2.54M | ﹤0.01% |
375,625
+26,567
| +8% | +$186K |
|
2734
Dutch Bros
BROS
$8.93B
| $2.54M | ﹤0.01% |
41,522
-171,068
| -80% | -$9.72M |
|
2735
Vital Farms
VITL
$495M
| $2.54M | ﹤0.01% |
79,575
+2,910
| +4% | +$102K |
|
2736
Envista
NVST
$4.61B
| $2.54M | ﹤0.01% |
116,975
-40,776
| -26% | -$837K |
|
|
MIAX
2737
Miami International Holdings
MIAX
$4.36B
| $2.53M | ﹤0.01% |
57,104
+41,202
| +259% | +$1.84M |
|
2738
QCR Holdings
QCRH
$1.73B
| $2.53M | ﹤0.01% |
30,423
+6,004
| +25% | +$473K |
|
2739
Metallus
MTUS
$900M
| $2.53M | ﹤0.01% |
147,533
+5,020
| +4% | +$86K |
|
2740
Hope Bancorp
HOPE
$1.83B
| $2.53M | ﹤0.01% |
230,890
+46,789
| +25% | +$504K |
|
2741
Neogen
NEOG
$2.5B
| $2.53M | ﹤0.01% |
361,259
+15,421
| +4% | +$97K |
|
2742
Hudbay
HBM
$11.8B
| $2.52M | ﹤0.01% |
127,190
+41,449
| +48% | +$701K |
|
2743
Gold Fields
GFI
$35.4B
| $2.52M | ﹤0.01% |
57,712
-7,200
| -11% | -$301K |
|
|
HTBK
2744
DELISTED
Heritage Commerce
HTBK
| $2.52M | ﹤0.01% |
209,735
+9,170
| +5% | +$99.5K |
|
2745
Healthcare Services Group
HCSG
$1.43B
| $2.52M | ﹤0.01% |
131,676
+18,531
| +16% | +$333K |
|
2746
iRadimed
IRMD
$1.11B
| $2.51M | ﹤0.01% |
25,849
+1,862
| +8% | +$160K |
|
2747
CALL
Invesco
IVZ
$13.9B
| $2.51M | ﹤0.01% |
+95,500
| New | +$2.33M |
|
|
LTC
2748
LTC Properties
LTC
$2.1B
| $2.5M | ﹤0.01% |
72,858
+6,759
| +10% | +$238K |
|
2749
Pebblebrook Hotel Trust
PEB
$2.04B
| $2.5M | ﹤0.01% |
221,176
-755,628
| -77% | -$8.32M |
|
|
NBP
2750
NovaBridge Biosciences American Depositary Shares
NBP
$216M
| $2.5M | ﹤0.01% |
628,923
+233,492
| +59% | +$1.03M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.